Hızla Yayılan Çoklu İlaca Dirençli Maya Mantarı: Candida auris
Candida auris, tanımlanmasından bu yana kısa bir süre içinde çeşitli ülkelerden rapor edilen ve çoklu ilaca direnç gösteren yeni bir Candida türüdür. İlk olarak dış kulaktan izole edildiği için bu ismi alan mantarın doğal rezervuarı bulunamamış, şu ana kadar sadece hastane ortamlarında izole edilmiştir. Konvansiyonel yöntemler ile yanlış tanımlanabilen mantarın gerçek prevalansı, bu nedenle bilinmemektedir. C. auris, diğer kandida türlerinde olduğu gibi kan dolaşımı enfeksiyonları, idrar yolu enfeksiyonu, otit, cerrahi yara enfeksiyonları, kateter ilişkili cilt apseleri, miyokardit, menenjit, kemik enfeksiyonları ve yara enfeksiyonları gibi çeşitli invaziv enfeksiyonlara neden olmakta ve birçok hastane salgınından sorumlu tutulmaktadır. Geniş spektrumlu antibiyotik ve antifungal ajan kullanımı, diabetes mellitus, abdominal ve vasküler cerrahi, merkezi venöz kateterlerin varlığı, idrar kateterizasyonu, postoperatif dren yerleştirme, kronik böbrek hastalığı, kemoterapi, kan transfüzyonları, hemodiyaliz, total parenteral beslenme, yoğun bakımda kalış süresi, immünsüpresif durum diğer enfeksiyonlarda olduğu gibi C. auris için de artan risk faktörlerini oluşturmaktadır. C. auris; adherans, biyofilm oluşumu, fosfolipaz ve proteinaz enzimleri gibi çeşitli virülans faktörlerine sahiptir ve yaptığı enfeksiyonlar yüksek mortalite ile sonuçlanabilmektedir. Dış yüzeylerde uzun süre canlı kalabilmesi ve dezenfektanlara kısmen dirençli olması, mantar ile kolonisazyon ve sonrasında enfeksiyonu kolaylaştırmaktadır. Çoğu izolat, yüksek flukonazol ve amfoterisin B MİK minimal inhibitör konsantrasyon değerleri göstermektedir. Ekinokandinlere direnç durumunun ise farklılık gösterdiği bildirilmiştir. Bazı izolatlar, üç ana antifungal sınıfa da direnç göstermekte ve persistan enfeksiyonlara neden olmaktadır. C. auris’in birinci basamak tedavisinde ekinokandin sınıfı antifungaller kullanılmaktadır. Ekinokandinlere direnç durumunda ise kombinasyon tedavileri önerilmektedir. Laboratuvarların rutin tanısında genel olarak yanlış tanımlanması, antifungal ajanlara direnç göstermesi ve küresel anlamda hızla yayılması bu patojen için endişe uyandırmaktadır. Bu derlemenin amacı, yeni tanımlanan bir tür olan C. auris’in mikrobiyolojik özellikleri, virülans faktörleri, antifungal direnç mekanizmaları ve küresel yayılımının irdelenmesi ile klinik açıdan farkındalık oluşturmaktır
Rapidly Spreading Multi-Drug Resistant Yeast: Candida auris
Candida auris is a new type of Candida that has been reported in several countries and has been resistant to multiple drugs in a short time since its identification. This fungus, whose natural reservoir cannot be found, is almost exclusively isolated in hospital settings. The actual prevalence of mushroom misidentifiable by conventional methods is therefore not known. As with other Candida species, C. auris causes various invasive infections such as bloodstream infections, urinary tract infection, otitis, surgical wound infections, catheter-associated skin abscesses, myocarditis, meningitis, bone infections and wound infections, and is responsible for many hospital outbreaks. Use of broad-spectrum antibiotics and antifungal agents, diabetes mellitus, abdominal and vascular surgery, presence of central venous catheters, urinary catheterization, postoperative drain placement, chronic kidney disease, chemotherapy, blood transfusions, hemodialysis, total parenteral nutrition, duration of intensive care unit, the immunosuppressive condition also constitutes risk factors for C. auris as in other infections. C. auris; adherence has various virulence factors such as biofilm formation, phospholipase and proteinase enzymes, and infections may result in high mortality. Survival of external surfaces and partial resistance to disinfectants facilitate colonization with fungi and subsequent infection. Most isolates show high at a finding of an elevated minimum inhibitory concentration MIC fluconazole and amphotericin B values. Resistance to echinocandins has been reported to differ. Some isolates are resistant to three major antifungal classes and cause persistent infection. In the first-line treatment of C. auris, echinocandin class antifungals are used. In case of resistance to echinocandins, combination therapies are recommended. The general misconfiguration of laboratory diagnoses, resistance to antifungal agents and rapid spread in the global sense arouses concern for this pathogen. The aim of this review is to describe C. auris, a newly described species; microbiological characteristics, virulence factors, antifungal resistance mechanisms and global dissemination are examined to create a clinical awareness.
___
- 1. Ku TSN, Walraven CJ, Lee SA. Candida auris:
disinfectants and implications for infection
control. Front Microbiol, 2018; 9: 726.
- 2. Satoh K, Makimura K, Hasumi Y, Nishiyama
Y, Uchida K, Yamaguchi H. Candida auris spp.
a novel ascomycetous yeast isolated from the
external ear canal of an inpatient in a Japanese
hospital. Microbiol Immunol, 2009; 53: 41–4.
- 3. Kim MN, Shin JH, Sung H, Lee K, Kim EC,
Ryoo N, et al. Candida haemulonii and closely
related species at 5 university hospitals in
Korea: identification, antifungal susceptibility,
and clinical features. Clin Infect Dis, 2009; 48:
57–61.
- 4. Lee WG, Shin JH, Uh Y, Kang MG, Kim SH,
Park KH, et al. First three reported cases of
nosocomial fungemia caused by Candida auris.
J Clin Microbiol, 2011; 49: 3139–42.
- 5. Kathuria S, Singh PK, Sharma C, Prakash A, Masih
A, Kumar A, et al. Multidrug-resistant Candida
auris misidentified as Candida haemulonii:
characterization by matrix-assisted laser
desorption ionization-time of flight mass
spectrometry and DNA sequencing and its
antifungal susceptibility profile variability by
Vitek 2, CLSI broth microdilution, and Etest
method. J Clin Microbiol, 2015; 53: 1823–30.
- 6. Chowdhary A, Voss A, Meis JF. Multidrugresistant Candida auris: “new kid on the block”
in hospital-associated infections? J Hosp Infect,
2016; 94: 209–12.
- 7. Kim TH, Kweon OJ, Kim HR, Lee MK. Identification
of uncommon Candida species using commercial
identification systems. J Microbiol Biotechnol,
2016; 26: 06–13.
- 8. Rudramurthy SM, Chakrabarti A, Paul RA, Sood
P, Kaur H, Capoor MR, et al. Candida auris
candidaemia in Indian ICUs: analysis of risk
factors. J Antimicrob Chemother, 2017; 72:
1794–801.
- 9. Ben-Ami R, Berman J, Novikov A, Bash E, ShachorMeyouhas Y, Zakin S, et al. Multidrug-resistant
Candida haemulonii and C. auris, Tel Aviv, Israel.
Emerg Infect Dis, 2017; 23: 195–203.
- 10. Osei SJ. Candida auris: a systematic review
and meta-analysis of current updates on
an emerging multidrug-resistant pathogen.
Microbiologyopen, 2018;7(4): e00578.
- 11. Welsh RM, Bentz ML, Shams A, Houston H, Lyons
A, Rose LJ, et al. Survival, persistence, and
isolation of the emerging multidrug-resistant
pathogenic yeast Candida auris on a plastic
health care surface. J Clin Microbiol, 2017; 55:
2996–3005.
- 12. Chauhan R, Loonker S. Synthesis, characterization
and biological evaluation of chitosan epoxy
n-methyl piperazine as antimicrobial agent. Int J
Pharm Sci Rev Res, 2017; 45: 266 –70.
- 13. Cortegiani A, Misseri G, Fasciana T, Giammanco
A, Giarratano A, Chowdhary A. Epidemiology,
clinical characteristics, resistance, and
treatment of infections by Candida auris. J
Intensive Care, 2018; 6: 69.
- 14. Borman AM, Szekely A, Johnson EM. Comparative
pathogenicity of United Kingdom isolates of the
emerging pathogen Candida auris and other
key pathogenic Candida species. Clin Sci and
Epidemiol, 2016;1: e00189–16.
- 15. Munoz JF, Gade L, Chow NA, Loparev VN, Juieng
P, Farrer RA, et al. Genomic basis of multidrugresistance, mating, and virulence in Candida
auris and related emerging species. bioRxiv,
2018: 299917.
- 16. Anonymous. https://www.cdc.gov/fungal/
candida-auris/recommendations.html, (Erişim
Tarihi: 15.05. 2019).
- 17. Jeffery-Smith A, Taori SK, Schelenz S, Jeffery K,
Johnson EM, Borman A. Candida auris incident
management team, Manuel R, Brown CS.
Candida auris: a review of the literature. Clin
Microbiol Rev, 2018; 31: e00029-17.
- 18. Anonymous. https://www.cdc.gov/fungal/
candida-auris/tracking-c-auris.html, (Erişim
Tarihi: 15.05. 2019).
- 19. Lockhart SR, Berkow EL, Chow N, Welsh RM.
Candida auris for the clinical microbiology
laboratory: not your grandfather’s Candida
species. Clin Microbiol Newsl, 2017; 39: 99–103.
- 20. Lockhart SR, Etienne KA, Vallabhaneni S, Farooqi
J, Chowdhary A, Govender NP, et al. Simultaneous
emergence of multidrug-resistant Candida auris
on 3 continents confirmed by whole-genome
sequencing and epidemiological analyses. Clin
Infect Dis, 2017;64(2): 134-40.
- 21. Sayeed MA, Farooqi J, Jabeen K, Awan S,
Mahmood SF. Clinical spectrum and factors
impacting outcome of Candida auris: a single
center study from Pakistan. BMC Infect Dis,
2019; 19: 384.
- 22. Morales-López SE, Parra-Giraldo CM, CeballosGarzón A, Martínez HP, Rodríguez GJ, ÁlvarezMoreno CA, et al. Invasive infections with
multidrugresistant yeast Candida auris,
Colombia. Emerg Infect Dis, 2017; 23(1): 162–4.
- 23. Çetin Ş, Sav H, Çelik İ, Bolat E, Afsar-Çagır F,
Bulut T, et al. Yoğun bakım ünitesinde gelişen
sağlık bakımı ile ilişkili Candida infeksiyonlarının
değerlendirilmesi. Turk Hij Den Biyol Derg,
2019; 76(2): 169-76.
- 24. Pappas PG, Kauffman CA, Andes DR, Clancy CJ,
Marr KA, Ostrosky-Zeichner L, et al. Clinical
practice guideline for the management of
candidiasis: 2016 update by the Infectious
Diseases Society of America. Clin Infect Dis,
2016; 15:62(4): e1-50.
- 25. Anonymous. https://www.cdc.gov/fungal/
candida-auris/c-auris-treatment.html, (Erişim
Tarihi: 15.05. 2019).
- 26. Azar MM, Turbett SE, Fishman JA, Pierce VM.
Donor-derived transmission of Candida auris
during lung transplantation. Clin Infect Dis,
2017; 65: 1040–2.
- 27. Vallabhaneni S, Kallen A, Tsay S, Chow N, Welsh
R, Kerins J, et al. Investigation of the first seven
reported cases of Candida auris, a globally
emerging invasive, multidrug-resistant fungusUnited States, May 2013- August 2016. Am J
Transplant, 2017;17: 296–9.
- 28. Larkin E, Hager C, Chandra J, Mukherjee
PK, Retuerto M, Salem I, et al. The emerging
pathogen Candida auris: growth phenotype,
virulence factors, activity of antifungals, and
effect of SCY-078, a novel glucan synthesis
inhibitor, on growth morphology and biofilm
formation. Antimicrob Agents Chemother, 2017;
61(5): pii: e02396-16.
- 29. Sherry L, Ramage G, Kean R, Borman A, Johnson
EM, Richardson MD, et al. Biofilm-forming
capability of highly virulent, multidrug-resistant
Candida auris. Emerg Infect Dis, 2017;23: 328–
31.
- 30. Borman AM, Szekely A, Johnson EM. Comparative
pathogenicity of United Kingdom isolates of the
emerging pathogen Candida auris and other key
pathogenic Candida species. MSphere, 2016;1:
e00189–16.
- 31. Aydemir Ö, Demiray T, Köroğlu M, Aydemir Y,
Altındiş M. Emerge of non-albicans Candida
species; evaluation of Candida species and
antifungal susceptibilities according to years.
Int J Med Sci, 2017; 28: 6.
- 32. Escandón P. Notes from the field: surveillance
for Candida auris Colombia, September 2016–
May 2017. Morb Mortal Wkly Rep, 2018;67:
459–60.
- 33. Escandón P, Chow NA, Caceres DH, Gade L,
Berkow EL, Armstrong P, et al. Molecular
epidemiology of Candida auris in Colombia
reveals a highlyrelated, country-wide
colonization with regional patterns in
amphotericin B resistance. Clin Infect Dis, 2019;
1: 68(1): 15-21.
- 34. Chowdhary A, Prakash A, Sharma C, Kordalewska
M, Kumar A, Sarma S, et al. A multicentre study
of antifungal susceptibility patterns among
350 Candida auris isolates (2009-17) in India:
role of the ERG11 and FKS1 genes in azole
and echinocandin resistance. J Antimicrob
Chemother, 2018;73: 891–9.
- 35. Mathur P, Hasan F, Singh PK, Malhotra R, Walia
K, Chowdhary A. Five-year profile of candidemia
at an Indian trauma center: high rates of
Candida auris blood stream infections. Mycoses,
2018;61: 674–80.
- 36. Morio F, Loge C, Besse B, Hennequin C, Le Pape
P. Screening for amino acid substitutions in
the Candida albicans Erg11 protein of azolesusceptible and azole-resistant clinical isolates:
new substitutions and a review of the literature.
Diagn Microbiol Infect Dis, 2010;66: 373–84.
- 37. Xiang M-J, Liu J-Y, Ni P-H, Wang S, Shi C, Wei
B, et al. Erg11 mutations associated with
azole resistance in clinical isolates of Candida
albicans. FEMS Yeast Res, 2013;13: 386–93.
- 38. Rhodes J, Abdolrasouli A, Farrer RA, Cuomo
CA, Aanensen DM, Armstrong- James D, et al.
Genomic epidemiology of the UK outbreak of
the emerging human fungal pathogen Candida
auris. Emerg Microbes Infect, 2018; 7:43.
- 39. Tsay S, Welsh RM, Adams EH, Chow NA, Gade L,
Berkow EL, et al. Notes from the field: ongoing
transmission of Candida auris in health care
facilities - United States, June 2016-May 2017.
MMWR Morb Mortal Wkly Rep, 2017; 66: 514–5.
- 40. Ruiz Gaitan AC, Moret A, Lopez Hontangas JL,
Molina JM, Aleixandre Lopez AI, Cabezas AH, et
al. Nosocomial fungemia by Candida auris: first
four reported cases in continental Europe. Rev
Iberoam Micol, 2017;34: 23–7.
- 41. Berkow EL, Angulo D, Lockhart SR. In vitro
activity of a novel glucan synthase inhibitor,
SCY-078, against clinical isolates of Candida
auris. Antimicrob Agents Chemother, 2017;61:
e00435–17.
- 42. Wiederhold, NP, Patterson HP, Tran BH, Yates
CM, Schotzinger RJ, Garvey EP. Fungal-specific
Cyp51 inhibitor VT-1598 demonstrates in vitro
activity against Candida and Cryptococcus
species, endemic fungi, including Coccidioides
species, Aspergillus species and Rhizopus
arrhizus. J Antimicrob Chemother, 2018, 73,
404–8.
- 43. Wiederhold NP, Lockhart SR, Najvar LK, Berkow
EL, Jaramillo R, Olivo M. The fungal cyp51-
specific ınhibitor vt-1598 demonstrates in vitro
and in vivo activity against Candida auris.
Antimicrob Agents Chemother, 2019; 63(3): pii:
e02233-18.
- 44. Basso V, Garcia A, Tran DQ, Schaal JB, Tran
P, Ngole D, et al. Fungicidal potency and
mechanisms of theta-Defensins against
multidrug-resistant Candida species. Antimicrob
Agents Chemother, 2018;62: e00111–8.
- 45. Hager CL, Larkin EL, Long L, Zohra Abidi F, Shaw
KJ, Ghannoum MA. In vitro and in vivo evaluation
of the antifungal activity of APX001A/APX001
against Candida auris. Antimicrob Agents
Chemother, 2018; 62 (3): pii: e02319-17.
- 46. Magobo RE, Naicker SD, Wadula J, Nchabeleng
M, Coovadia 5, Hoosen A, et al. Detection of
neonatal unit clusters of Candida parapsilosis
fungaemia by microsatellite genotyping: results
from laboratory-based sentinel surveillance,
South Africa, 2009–2010. Mycoses, 2017; 60:
320–7.
- 47. Pinhati HM, Casulari LA, Souza AC, Siqueira
RA, Damasceno CM, Colombo AL. Outbreak of
candidemia caused by fluconazole resistant
Candida parapsilosis strains in an intensive care
unit. BMC Infect Dis, 2016; 16: 433.
- 48. Lupetti A, Tavanti A, Davini P, Ghelardi E, Corsini
V, Merusi I, et al. Horizontal transmission of
Candida parapsilosis candidemia in a neonatal
intensive care unit. J Clin Microbiol, 2002; 40
(7): 2363–9.
- 49. Forsberg K, Woodworth K, Walters M, Berkow
EL, Jackson B, Chiller T, et al. Candida auris:
the recent emergence of a multidrug-resistant
fungal pathogen. Med Mycol, 2019, 57(1): 1–12.
- 50. Richardson M, Richardson MD, Warnock DW.
Fungal Infection: Diagnosis and Management,
4th ed. Chichester: John Wiley & Sons Ltd,
2012.
- 51. Biswal M, Rudramurthy SM, Jain N Shamanth AS,
Sharma D, Jain K, et al. Controlling a possible
outbreak of Candida auris infection: lessons
learnt from multiple interventions. J Hosp
Infect, 2017; 97: 363–70.
- 52. Schelenz S, Hagen F, Rhodes JL Abdolrasouli
A, Chowdhary A, Hall A, et al. First hospital
outbreak of the globally emerging Candida auris
in a European hospital. Antimicrob Resist Infect
Control, 2016; 5: 35.
- 53. Anonymous. http://www.promedmail.org/
post/20180425.5767936, (Erişim Tarihi: 15.05.
2019)